Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics

Front Med (Lausanne). 2021 Apr 13;8:641260. doi: 10.3389/fmed.2021.641260. eCollection 2021.

ABSTRACT

Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to "disarm" rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit from these new agents. The application of pathogen genomics can facilitate the rational utilization of advanced therapeutics for infectious diseases. The development of genomic assessment of VAD targets is essential to support the early stages of VAD diffusion into infectious disease management. Genomic identification and characterization of VAD targets in clinical isolates can augment antimicrobial stewardship and pharmacovigilance. Personalized genomics guided use of VAD will provide crucial policy guidance to regulating agencies, assist hospitals to optimize the use of these expensive medicines and create market opportunities for biotech companies and diagnostic laboratories.

PMID:33928102 | PMC:PMC8076527 | DOI:10.3389/fmed.2021.641260